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“P
ublishing results in the 
traditional paper based way 
in a journal hides too much 
information.” This is the verdict of 
Markus Ruschhaupt and colleagues 
who, in a paper in Statistical Applications 
in Genetics and Molecular Biology (3: 
article 37), discuss a paradigm for the 
presentation of complex data—in this 
case, from microarray analyses. The 
title of the article, “A Compendium 
to Ensure Reproducibility in High-
Dimensional Classiﬁ  cation Tasks,” 
may not lend itself easily to a clinical 
audience, but the underlying message to 
clinicians could not be more important: 
that, currently, studies involving large 
datasets, especially ones that have a 
clinical outcome, are so poorly reported 
(or possibly so poorly done) that many 
are not reproducible. This problem was 
also the topic of a recent meeting in 
Heidelberg, “Best Practice in Microarray 
Studies” (http:⁄⁄www.biometrie.
uni-heidelberg.de/workshops/
bestpractice/index.htm). 
As microarrays have become 
mainstream research tools in biology 
and medicine, the large datasets and 
complex analyses from these studies 
have presented challenges: for authors 
in analyzing the data, for reviewers and 
editors in deciding on the suitability of 
papers for publication, for journals in 
determining how much data needs to 
be presented within the paper itself, for 
other researchers in reproducing the 
data, and, ﬁ  nally, for readers in deciding 
how to assess the data presented. 
The results from several high-proﬁ  le 
papers have already proved difﬁ  cult to 
reproduce, even by those with sufﬁ  cient 
time and computing expertise.
Where do such analyses leave the 
new science of molecular pathology? 
Ruschhaupt and colleagues comment 
that “the literature on the induction 
of prognostic proﬁ  les from microarray 
studies is a methodological wasteland.” 
Much the same could be said of other 
applications of molecular biology to 
clinical samples. A systematic review of 
molecular and biological tumor markers 
in neuroblastoma (Clin Cancer Res 10: 
4–12) found that its conclusions were 
limited by “small sample sizes, poor 
statistical reporting, large heterogeneity 
across studies…and publication bias.” 
John Ioannidis and colleagues (Lancet 
362: 1439–1444) did a similar analysis of 
30 microarray studies with major clinical 
outcomes in cancer. They showed that 
the studies were small—median sample 
size was 25 patients, and validation 
was incomplete in most studies. 
They recommended that molecular 
prognostic studies be classiﬁ  ed as 
phase 1 (early exploratory probing 
associations), phase 2 (exploratory with 
extensive analyses), or phase 3 (large 
conﬁ  rmatory studies with pre-stated 
hypotheses and precise quantiﬁ  cation of 
the magnitude of the effect), and that 
only studies that had undergone phase 
3 testing should be considered robust 
enough for use in clinical practice. Most 
current studies should be considered as 
phase 1 or, at best, phase 2.
So, despite considerable hype, the 
published studies are far from the level 
of evidence that would be accepted 
for virtually any other medical test. In 
a review in 2003 (Hematology [Am 
Soc Hematol Educ Program] 2003: 
279–293), Rita Braziel and colleagues 
concluded, “rapid identiﬁ  cation and 
neutralization of spurious results 
is essential to prevent them from 
becoming accepted facts.”
But these problems are not new 
in medical research. In 1994 (BMJ 
308: 283-284), Doug Altman, who 
was instrumental in developing the 
CONSORT guidelines for reporting of 
clinical trials, said that “huge sums of 
money are spent annually on research 
that is seriously ﬂ  awed through 
the use of inappropriate designs, 
unrepresentative samples, small samples, 
incorrect methods of analysis, and faulty 
interpretation,” and “that quality control 
needs to be built in from the start rather 
than the failures being discarded.”
So how can we ensure that the wealth 
of data pouring out of microarray and 
other molecular diagnostic studies is 
turned into meaningful knowledge? 
The Microarray Gene Expression 
Data Society has proposed a set of 
guidelines (MIAME) for the reporting 
of microarray data, and that all such 
data should be deposited in public 
databases. But as Ruschhaupt and others 
have shown, disclosure of results and 
data is not enough, since there is little 
consensus on the appropriate statistical 
analyses and many are developed on 
a case by case basis, which may not 
be reproducible, even by the authors. 
Some researchers advocate the use of 
standard statistical packages, which 
allows the reader to repeat an entire 
analysis quickly and, hence, assess the 
robustness of the results. Some authors 
have produced a transcript of their 
statistical analyses as a supplement to 
their articles (e.g., Nucleic Acids Res 32: 
e50). At the very least authors should 
have a protocol with a prespeciﬁ  ed 
plan for patient selection and statistical 
analysis—accepted practice for clinical 
trials, but not yet for other medical 
research. An ultimate aim for reporting 
would be the type of compendium 
discussed by Ruschhaupt and 
colleagues—“an interactive document 
that bundles primary data, statistical 
processing methods, ﬁ  gures, and 
derived data together with the textual 
documentation and conclusions.” 
One such compendium is illustrated 
in a paper by Robert Gentleman (Stat 
Appl Genet Mol Biol 4: article 2). PLoS 
Medicine is keen to work with authors 
towards making such reporting possible. 
But although the time might have gone 
when the two-dimensional journal 
article could sufﬁ  ce for complex papers, 
clinicians should nonetheless apply the 
same critical assessment that they would 
for any other clinical tool. If a result is 
too good to be true, it probably is.  
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